Icon (ICLR) Stock Price, News & Analysis

Company Overview

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions. The company leverages proprietary technology platforms and advanced data analytics to optimize trial efficiency, support patient recruitment and enhance site management, with the goal of accelerating development timelines and mitigating risks.

Founded in 1990 by John F. Climax, Icon is headquartered in Dublin, Ireland, and has expanded through organic growth and strategic acquisitions to serve clients around the world. The company maintains regional offices and operational centers across North America, Europe, Asia-Pacific, Latin America and the Middle East, providing localized regulatory support and scientific expertise to a diverse client base.

Icon’s leadership team is headed by Chief Executive Officer Steve Cutler, who joined the company in 2017 and brings extensive experience in clinical research and development. Under his stewardship, Icon continues to invest in digital innovation, strategic partnerships and talent development to meet the evolving needs of drug and device developers globally.

Key Stats

• Today's Range: $164.42 to $170.40
• 50-Day Range: $113.55 to $175.05
• 52-Week Range: $66.57 to $211.00
• Volume: 525,263 shs
• Average Volume: 925,382 shs
• Market Capitalization: $12.92 billion
• P/E Ratio: 30.03
• Dividend Yield: N/A
• Price Target: $173.19
• Consensus Rating: Hold

Icon Stock Analysis - MarketRank™

Icon scored higher than 46% of companies evaluated by MarketBeat, and ranked 452nd out of 845 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Hold

Consensus Rating

Icon has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 9 buy ratings, 6 hold ratings, and 3 sell ratings.

Upside/Downside

The consensus price target for Icon is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Icon has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 14.00%

Earnings Growth

Earnings for Icon are expected to grow by 14.00% in the coming year, from $9.43 to $10.75 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Icon is 30.03, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.97.

Price to Earnings Ratio vs. Sector

The P/E ratio of Icon is 30.03, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.42.

Price to Earnings Growth Ratio

Icon has a PEG Ratio of 8.12. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Icon has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.56% of the float of Icon has been sold short.

Short Interest Ratio / Days to Cover

Icon has a short interest ratio ("days to cover") of 2.92, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Icon has recently increased by 7.76%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Icon does not currently pay a dividend.

Dividend Growth

Icon does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: -0.17

News Sentiment

Icon has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Icon this week, compared to 4 articles on an average week.

Search Interest

2 people have searched for ICLR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

4 people have added Icon to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Icon insiders have not sold or bought any company stock.

Percentage Held by Insiders

44.00% of the stock of Icon is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.61% of the stock of Icon is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 6/23/2026
• Today: 7/09/2026
• Next Earnings (Estimated): 7/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:ICLR
• Previous Symbol: NASDAQ:ICLR
• CIK: 1060955
• Web: www.iconplc.com
• Phone: (531) 291-2000
• Fax: 353-1247-6260
• Employees: 40,100
• Year Founded: 1990

Price Target and Rating

• Average Price Target for Icon: $173.19
• High Price Target: $240.00
• Low Price Target: $100.00
• Potential Upside/Downside: +2.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): $5.62
• Trailing P/E Ratio: 30.03
• Forward P/E Ratio: 17.90
• P/E Growth: 8.12
• Net Income: $229.34 million
• Net Margins: 5.35%
• Pretax Margin: 2.42%
• Return on Equity: 8.73%
• Return on Assets: 4.96%

Debt

• Debt-to-Equity Ratio: 0.31
• Current Ratio: 1.14
• Quick Ratio: 1.14

Sales & Book Value

• Annual Sales: $8.25 billion
• Price / Sales: 1.57
• Cash Flow: $17.19 per share
• Price / Cash Flow: 9.82
• Book Value: $120.07 per share
• Price / Book: 1.41

Miscellaneous

• Outstanding Shares: 76,570,000
• Free Float: 42,878,000
• Market Cap: $12.92 billion
• Optionable: Optionable
• Beta: 1.22